US1374041093

Candel Therapeutics Announces Proposed $100 Million Public Offering

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical…

1 week ago

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 02, 2026 16:05 ET  | Source: Candel Therapeutics NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc.…

4 weeks ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

October 14, 2025 08:05 ET  | Source: Candel Therapeutics NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc.…

5 months ago